logo
Castle Biosciences Celebrates Skin Cancer Awareness Month

Castle Biosciences Celebrates Skin Cancer Awareness Month

Yahoo07-05-2025

Aaron Farberg, M.D., FAAD, double board-certified dermatologist, Mohs surgeon and chief medical officer of Bare Dermatology in Dallas, will lead the discussion, joined by dermatology interest group students Mitchell Hanson and Brianna Speigel. Topics will include navigating a diagnosis, emotional support resources, survivorship planning and how patients and caregivers can more effectively advocate for melanoma care. Registration details can be found here .
Empowering Patients and Caregivers: IMPACT Melanoma Virtual Patient Symposium Castle is proud to continue its long-standing partnership with IMPACT Melanoma by sponsoring the organization's upcoming virtual patient symposium, 'Melanoma Diagnosis: A Toolkit to Support the Journey.' The event will be held on Wednesday, May 21, 2025, at 6 p.m. ET , and has been designed to provide individuals newly diagnosed with melanoma — and their support networks — with practical tools, resources and compassionate guidance to navigate the melanoma journey.
'At Castle, our mission is rooted in delivering clinically actionable information to patients and their clinical care teams — and that begins with awareness and education,' said Derek Maetzold, president and chief executive officer of Castle Biosciences. 'By supporting organizations like IMPACT Melanoma and sharing real patient stories like Leah's, we aim to drive conversations around early detection and personalized risk assessment in an effort to help improve patient outcomes.'
FRIENDSWOOD, Texas, May 07, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is recognizing Skin Cancer Awareness Month this May by supporting a series of initiatives designed to raise awareness, educate patients and families and empower those impacted by skin cancer.
Story Continues
'This symposium was created to meet people where they are — at a vulnerable moment in their lives,' said Deb Girard, executive director of IMPACT Melanoma. 'We want everyone who attends, whether they are just beginning their journey or supporting someone who is, to walk away feeling more informed, supported and empowered.'
Leah's Story: Living Confidently with the Support of DecisionDx®-Melanoma
Improving patient care is at the heart of Castle's mission. This month, Castle is sharing the powerful story of Leah Adams, a melanoma survivor who used Castle's DecisionDx-Melanoma test to better understand her predicted risk of recurrence. 'People don't understand how serious melanoma is,' said Adams. 'The DecisionDx-Melanoma test allows you to really see your risk of recurrence — whether it's high- or low-risk — so you can do everything possible to protect your largest organ. Having the reassurance of the low-risk result helps me move forward and be able to show up for my family and for myself.'
Leah's full story can be viewed here.
Walking Together Toward a Cure: Castle Rallies for Melanoma Awareness Across the Nation
As part of its commitment to advancing skin cancer awareness, Castle is proud to continue its support of AIM at Melanoma and the Melanoma Research Foundation by participating in multiple advocacy walks throughout the month of May. Taking place across the country, these events bring together survivors, caregivers, clinicians and advocates to raise critical funds for research, education and outreach — united by a shared goal of finding a cure.
Raising National Awareness: USA TODAY 2025 Skin Health Campaign
Castle is also participating in the 2025 Skin Health Campaign by USA TODAY. The Company is collaborating on an article titled 'Transforming Skin Cancer and Melanoma Outcomes,' which will appear in the May 30 print edition of USA TODAY and in the digital campaign on usatoday.com and Future of Personal Health. The article features Shannon Trotter, D.O., FAAD, board-certified dermatologist and host of the Derm-it Trotter! Don't Swear About Skincare podcast, and melanoma advocate Leah Adams, and highlights the growing role of diagnostic testing in guiding personalized care decisions for individuals diagnosed with melanoma.
More information about Castle's tests for patients with skin cancer can be found at www.CastleBiosciences.com.
About IMPACT Melanoma
IMPACT Melanoma, a national non-profit 501(c)(3) organization, is the nation's leading non-profit dedicated to significantly reducing melanoma in the United States and saving lives. The focus is on prevention education programs that include customized and integrated programs for communities. In addition to skin cancer prevention education and programs, the organization is committed to supporting melanoma patients and their families and advocating for and influencing urban development policies to address shade equity in America. To learn more about IMPACT Melanoma, visit https://impactmelanoma.org/.
About AIM at Melanoma
Founded in 2004, AIM at Melanoma is a global foundation dedicated to finding more effective treatments and, ultimately, the cure for melanoma. By directing and funding paradigm-shifting research initiatives — educating patients, healthcare professionals, and the public — and advocating for survivors and their families, AIM at Melanoma's goal is to end this disease in our lifetime while improving the lives of those it affects. AIM at Melanoma is dedicated to innovation in melanoma research, information and support, and legislation, policy and advocacy. For more information, visit AIMatMelanoma.org.
About Melanoma Research Foundation
The Melanoma Research Foundation (MRF) is a 501(c)(3) non-profit organization and the largest independent organization devoted to melanoma. Committed to the support of medical research to develop effective treatments and eventually a cure for melanoma, the MRF also educates patients and physicians about the prevention, diagnosis and treatment of cutaneous melanoma and the melanoma rare subtypes. The MRF is a dedicated advocate for the melanoma community, helping to raise awareness of this disease and the need for a cure. To learn more about the MRF, visit https://melanoma.org/.
About DecisionDx-Melanoma
DecisionDx-Melanoma is a 31-gene expression profile risk stratification test. It is designed to inform two clinical questions in the management of cutaneous melanoma: a patient's individual risk of sentinel lymph node (SLN) positivity and a patient's personal risk of melanoma recurrence and/or metastasis. By integrating tumor biology with clinical and pathologic factors using a validated proprietary algorithm, DecisionDx-Melanoma is designed to provide a comprehensive and clinically actionable result to guide risk-aligned patient care. DecisionDx-Melanoma has been shown to be associated with improved patient survival and has been studied in more than 10,000 patient samples. DecisionDx-Melanoma's clinical value is supported by more than 50 peer-reviewed and published studies, providing confidence in disease management plans that incorporate the test's results. Through March 31, 2025, DecisionDx-Melanoma has been ordered more than 200,000 times for patients diagnosed with cutaneous melanoma. More information about the test and disease can be found at https://CastleBiosciences.com/.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. These forward-looking statements include, but are not limited to, statements concerning: Castle's ability to (i) raise awareness, educate patients and families and empower those impacted by skin cancer and (ii) deliver actionable information to patients and their clinical care teams; and DecisionDx-Melanoma's ability to (i) provide comprehensive, personalized results to guide risk-aligned management decisions for patients with stage I-III cutaneous melanoma and (ii) help clinicians make more informed, more precise treatment decisions. The words 'believe,' 'can,' 'could,' 'potential' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results obtained in these studies, including with respect to the discussion of our tests in this press release; actual application of our tests may not provide the aforementioned benefits to patients; and the risks set forth under the heading 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each filed or to be filed with the SEC, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
A video accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/c6e1c2a7-5df4-42dc-9cbe-bf5f94dce809

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Yahoo

timean hour ago

  • Yahoo

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 18, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit and enter the 16-digit control number found in their proxy materials. Guests may also access the meeting in listen-only mode. No control number is required for guests. Webcast Information: Date: Wednesday, June 18, 2025 Time: 9:30 a.m. ET A live webcast and replay will be accessible from the Company's website at and at About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. MiNK's proprietary platform is designed to restore immune balance and drive cytotoxic immune responses across cancer, immune-mediated diseases, and pulmonary immune failure. MiNK's lead asset, AGENT-797, is an off-the-shelf, allogeneic iNKT cell therapy currently in clinical development for the treatment of graft-versus-host disease (GvHD), solid tumors, and critical pulmonary immune collapse. MiNK is also advancing a pipeline of T cell receptor (TCR)-based therapies and neoantigen discovery tools that enable tumor- and tissue-specific immune activation with broad potential application. With a scalable, cryopreserved manufacturing process and a differentiated mechanism that bridges innate and adaptive immunity, MiNK is committed to developing next-generation immune reconstitution therapies that are accessible, durable, and applicable across a wide range of indications. For more information, visit or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels. Investor Contact917-362-1370 investor@ Media Contact781-674-4428communications@ in to access your portfolio

Odyssey bails on public listing as US IPO landscape stutters
Odyssey bails on public listing as US IPO landscape stutters

Yahoo

timean hour ago

  • Yahoo

Odyssey bails on public listing as US IPO landscape stutters

Odyssey Therapeutics is unlikely to join the 2025 class of biotechs hitting the stock exchanges after the company withdrew its registration statement for an initial public offering (IPO). The autoimmune and inflammatory disease specialist was one in a wave of biotechs to reveal IPO ambitions in January 2025. While Sionna Therapeutics, a biopharma that filed IPO paperwork at the same time, went on to close a nearly $220m IPO in February, Odyssey has bailed on a public listing. Odyssey did not disclose the number of its common stock shares it was offering, nor the price at which the IPO would conduct on each share. The Form S-1, a registration form with the US Securities and Exchange Commission (SEC) for companies carrying out public offerings, only mentioned that the listing would have occurred on the Nasdaq. Odyssey was eyeing an IPO as a way to fund its pipeline, headed by RIPK2 inhibitor OD-07656 that was set for Phase II trials for ulcerative colitis treatment, both as a monotherapy and in combination with Takeda's blockbuster Entyvio (vedolizumab). As per its IPO prospectus in January, the monotherapy trial was set to commence in Q1 2025, with the combo trial slated for the same quarter in 2026. Two pre-clinical programmes also stood to benefit from cash generated from the IPO. In its notice to the SEC outlining the withdrawal of the registration statement, Odyssey stated it is because it is 'not in the best interests of the company to conduct the proposed offering at this time'. The IPO U-turn is the first sign that the health of the IPO landscape could be suffering in the wake of economic fallout from US President Donald Trump's policies. Indeed, it consolidates predictions made by one GlobalData analyst earlier this year. In April, GlobalData business fundamentals analyst Alison Labya said: 'The Trump administration has introduced uncertainty to the biopharmaceutical industry across healthcare policies, drug pricing reforms, and regulatory frameworks, all of which could impact investor confidence. 'Additionally, Trump's recent tariff announcement on imports from Canada, Mexico, and China has led to increased market volatility, potentially delaying IPOs as investors await the countries' responses to the tariffs.' Biotech IPOs saw a strong recovery in 2024, with a total raise of $8.52bn, up 68.4% from $5.06bn raised in 2023. It was the highest total IPO value raised since 2021, with the rebound driven by US Federal Reserve interest rate cuts. The uptick continued into 2025, with Sionna joined by Maze Therapeutics and Metsera Therapeutics. U-turning on IPOs is rare, but Odyssey is not the only biotech to bail on a public listing in the past year. Australian biotech Telix Pharmaceuticals withdrew its US public listing at the last minute in June 2024, also citing unfavourable market conditions at the time. "Odyssey bails on public listing as US IPO landscape stutters" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

Inspire Veterinary Partners Announces AI Integration into Practice Management Software in Partnership with Leading Software Provider Covetrus
Inspire Veterinary Partners Announces AI Integration into Practice Management Software in Partnership with Leading Software Provider Covetrus

Indianapolis Star

time2 hours ago

  • Indianapolis Star

Inspire Veterinary Partners Announces AI Integration into Practice Management Software in Partnership with Leading Software Provider Covetrus

New software integration is among the first multi-unit operators to roll out AI note integration directly into the Company's medical software VIRGINIA BEACH, VA / ACCESS Newswire Inspire Veterinary Partners, Inc. (Nasdaq:IVP) ('Inspire' or the 'Company'), an owner and provider of pet health care services throughout the U.S., announces the integration of a new artificial intelligence (AI) platform in partnership with leading software provider Covetrus into its medical software. The new platform is designed to perform a variety of administrative tasks, including AI-based dictation tools, empowering the Company's veterinarians and technicians with the ability to focus on their clients and patients rather than note taking and toggling between screens. As one of the first multi-unit operators – and the first publicly traded multi-unit operator – to implement the integration at scale, the services provided by the platform are expected to provide value to Inspire's clinics in the form of reduced administrative workload. 'Inspire wants our veterinarians focusing on the things that matter: the clients and pets they serve,' shared Dr Alexandra Quarti, Vice President of Medical Operations. 'Covetrus' expansion of our practice management software to include AI-driven tools allows our vets to do just that by focusing on quality of care instead of note taking or proper inter-practice communication. With auto-generated notes and pre-appointment summaries, we are confident our clinics will be even better prepared to give top-of-the-line pet care for each and every appointment.' Contrary to other veterinary consolidators, Inspire made the strategic investment to implement one practice management software (PiMS), Covetrus Pulse, across all of its clinics for the benefit of efficiency, KPI consistency, and business growth with all the clinics working from one trusted platform. Now, Inspire is implementing the brand new Covetrus AI platform across all of its hospitals. The platform provides AI-based dictation tools for efficient medical note taking which will allow veterinarians to focus on the clients and pets they serve. 'At Covetrus, we have been rolling out AI-powered tools within Covetrus Pulse and delivering significant benefits, including at least 6 hours per vet per week time savings, improved staff efficiency, and revenue growth for practices,' said Scot Gillespie, Covetrus Chief Product and Technology Officer and General Manager of Software Business. 'The adoption of AI tools isn't about replacing expertise; it's about augmenting it and freeing up veterinary professionals and staff for more personalized attention, and to create a more efficient and less stressful workplace for veterinary staff – letting them focus on delivering exceptional, compassionate care to pets. Covetrus' AI platform will be able to provide the following services and more: Ambient Listening & Auto-Generated SOAP (Subjective, Objective, Assessment, and Plan) Notes – Covetrus AI-powered transcription captures real-time conversations during appointments and auto-generates SOAP notes, saving valuable time per visit and allowing veterinarians to focus on pet care instead of typing good notes. Pre-Appointment Summaries – The AI platform generates concise patient summaries based on practice management system (PiMS) data, allowing veterinarians to prepare more efficiently before appointments without significant time to review previous charts. Treatment Boards – The AI PiMS programs enhances care team collaboration by providing real-time updates on patient treatments, ensuring seamless communication across the practice. Inspire expects these services to provide its clinics the ability to see more patients while providing consistent world-class medicine, reducing the administrative workload on its staff, and improving the quality of work life for its veterinarians. About Covetrus Covetrus is a technology-enabled practice improvement company, servicing veterinary clinics around the world. Our mission is to improve the financial and clinical outcomes for veterinarians. Our comprehensive practice improvement solutions and tools simplify every touchpoint in a veterinarian's practice-from pre-visit to post-appointment-to deliver a connected experience that helps veterinarians compete effectively and grow their practice. Through the VetSuite network, members become part of an exclusive community, gain access to exclusive events, trainings, and education, and through our collective buying power, achieve lower costs. Covetrus is headquartered in Portland, Maine with more than 5,000 employees serving over 100,000 customers around the globe and is owned by Clayton, Dubilier & Rice (CD&R), and TPG. With 60 years of history and heritage, Covetrus is the only organization to provide a one-stop, truly comprehensive solution to drive better financial and healthcare outcomes for veterinary practices. About Inspire Veterinary Partners, Inc. Inspire Veterinary Partners is an owner and provider of pet health care services throughout the US. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care. For more information, please visit: Facebook | LinkedIn | X Forward-Looking Statements This press release contains forward-looking statements regarding the Company's current expectations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, statements by the Company relating to the completion of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds from the offering, receipt of Stockholder Approval as well as risks and uncertainties related to the satisfaction of customary closing conditions related to anticipated acquisitions, or factors that result in changes to the Company's anticipated results of operations related to acquisitions. These and other risks and uncertainties are described more fully in the section captioned 'Risk Factors' in the Company's public filings made with the Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Investor Contact CoreIR Matt Blazei 516-386-0430 mattb@ Press Contact CORE IR Matthew Cossel pr@ General Inquires Morgan Wood Mwood@ SOURCE: INSPIRE VETERINARY PARTNERS, INC.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store